Drugs / PM1009
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05607563 | Nov 2022 → Nov 2023 | — | BioNTech SE | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06584071 | Dec 2024 → Oct 2026 expected | hepatocellular carcinoma | BioNTech SE | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PM1009 | “Combination regimen：PM8002 combined with PM1009” NCT06584071 ↗ |
| Route | Intravenous | “Participants receive PM1009 intravenously, every 2 weeks” NCT05607563 ↗ |